Spotlight on denosumab in postmenopausal osteoporosis

BioDrugs

Volumn 25, Issue 4, 2011, Pages 261-264

  Moen, Marit D ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Denosumab; Osteoporosis

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO;

BONE DENSITY; BONE TURNOVER; CELL FUNCTION; CELL SURVIVAL; CELLULITIS; CONCUSSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FALLING; FLATULENCE; HIP FRACTURE; HUMAN; INFECTION; NEOPLASM; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND;

EID: 80051499538     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11207100-000000000-00000     Document Type: Review

References (17)

1. Prolia™ (denosumab) injection, for subcutaneous use: US prescribing information. Thousand Oaks (CA): Amgen Inc., 2010
2. Prolia 60 mg solution for injection in a pre-filled syringe: EU summary of product characteristics. Breda: Amgen Europe B.V., 2010 May 26
3. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas 2010 Jun; 66 (2): 182-6
4. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009 Feb; 24 (2): 182-95
5. Ominsky MS, Schroeder J, Jolette J, et al. Decreased bone turnover and porosity are associated with improved bone strength in ovariectomized (OVX) cynomolgus monkeys treated with denosumab, a fully human RANKL antibody [abstract no. S409]. J Bone Miner Res 2007 Sep 1; 22 Suppl. 1: 126
6. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010 Oct; 25 (10): 2256-65
7. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010 Aug; 25 (8): 1886-94
8. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004 Jul; 19 (7): 1059-66 (Pubitemid 41110556)
9. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 Aug 20; 361 (8): 756-65
10. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009 Jan; 24 (1): 153-61
11. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010 Jan; 25 (1): 72-81
12. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008 Aug; 43 (2): 222-9
13. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 2010; 21: 837-46
14. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010 Jul; 47 (1): 34-40
15. Jö nsson B, Ström O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011 Mar; 22 (3): 967-82
16. Strom O, Macarios D, Badamgarav E, et al. A UK denosumab cost-effectiveness model incorporatingFRAXand adherence [abstract no. A09001963]. 31st Annual Meeting of the American Society for Bone and Mineral Research; 2009 Sep 11-15; Denver (CO)
17. Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011; 28 (1): 63-82